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Abstract
The Bcl-2 family, including antiapoptotic and proapoptotic members, plays key regulating roles in programmed cell death. We report
the characterization of a new member of the bcl-2 family, encoded by herpesvirus of turkeys (HVT). The product of this gene shares 80%
homology with Nr-13, an apoptosis inhibitor, which is overexpressed in avian cells transformed by the v-src oncogene. This new gene, that
we propose to call vnr-13, is the first member of the bcl-2 family to be isolated among -herpesviruses. Results from cells expressing the
HVT-vnr-13 gene product show that the encoded protein inhibits apoptosis and also reduces the rate of cellular proliferation. Contrary to
all bcl-2 homologues found in -herpesvirus, which are intronless, vnr-13 has the same organization as the cellular nr-13 gene. Hence, the
HVT vnr-13 gene may have been acquired from a reverse transcriptase product of an unspliced precursor RNA, or via direct recombination
with the host chromosomal DNA.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Apoptosis is a natural process essential to the develop-
ment of multicellular organisms (Jacobson et al., 1997).
During development and in adults, apoptosis allows rapid
elimination of unwanted cells and plays a major role in the
immune response (Osborne, 1996). Deregulation of apopto-
sis can lead to degenerative disorders or tumor formation
(Thompson, 1995). Thus, a complete understanding of this
complex phenomenon is of significant developmental and
therapeutic interest.
In most cases, apoptosis is due to the activation of a
cysteine protease (caspase) cascade, following death-induc-
ing stimuli (Shi, 2001). Caspase activation can be blocked
by Bcl-2, the canonic member of a family of apoptosis
regulators. Current data suggest that ordered balance be-
tween proapoptotic and antiapoptotic activities of the Bcl-2
family of proteins regulates the decision of a cell to survive
or die (Farrow and Brown, 1996). This family of proteins
forms a checkpoint upstream of mitochondrial dysfunction
and caspase activation (Bossy-Wetzel and Green, 1999).
Most Bcl-2-like proteins have a C-terminal hydrophobic
domain that stabilizes their interaction with intracellular
membranes (Suzuki et al., 2000). These proteins interact
with the outer mitochondrial membrane and prevent the
release of caspase activators from the mitochondria (Anton-
sson and Martinou, 2000). However, a number of death induc-
ers, such as the TNF-1 family of cytokines, induce apoptosis
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1 Abbreviations: TNF: tumor necrosis factor; HHV8: human herpesvi-
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independently of the mitochondria, and this is only partly
prevented by Bcl-2 family members (Huang et al., 1999).
Stimulation of apoptosis is one of the host defense mech-
anisms against viral infections. Apoptosis of infected cells
often cooperates with inflammation to prevent virus propa-
gation or contributes directly to viral pathogenesis (Lewis et
al., 1996). A number of viral strategies evolved to inhibit
cell death, thus allowing efficient virus propagation (Gillet
and Brun, 1996). Cowpox virus and baculovirus encode
substrate analogues of caspases, which act as enzyme in-
hibitors (Ray et al., 1992). Retrovirus infection can lead to
the expression of bcl-2-like genes by the host cell, e.g., the
Rous sarcoma virus activates the expression of the apoptosis
inhibitor Nr-13 in avian cells (Gillet et al., 1995). Herpes-
viruses, involved in a number of cancers, use different
strategies. For example, viral homologues of Bcl-2 with
antiapoptotic effect are encoded by -herpesviruses, EBV
(Henderson et al., 1993; Marshall et al., 1999), HHV8
(Cheng et al., 1997), HVP (Meseda et al., 2000), HVS
(Derfuss et al., 1998), and MHV-68 (Virgin et al., 1997).
However, similarity between the viral and cellular bcl-2-
like sequences is low (about 20% identity at the amino acid
level), suggesting that they diverged rapidly during evolu-
tion. In contrast, - and -herpesviruses i.e., HSV1 and
CMV, respectively) encode inhibitors of apoptosis, which
do not belong to the Bcl-2 family (Zhu et al., 1995; Aubert
and Blaho, 2001; Yu and Alwine, 2002). In addition to
herpesviruses, adenoviruses and african swine fever virus
have pirated Bcl-2 homologues, suggesting that this anti-
death function is crucial to the virus life cycle (Haig, 2001).
These viral homologues probably act to prolong cell sur-
vival, thereby maximizing the production of progeny virus
and facilitating virus persistence (Dawson et al., 1998).
An open reading frame potentially encoding a close
homologue of the apoptosis inhibitor Nr-13 has been re-
cently identified in the genome of the avian -herpesvirus,
herpesvirus of turkeys (HVT) (Kingham et al., 2001;
Afonso et al., 2001). HVT is used as a vaccine strain to
control Marek’s disease virus (MDV), which causes acute
lymphoma and immune suppression in chickens (Witter,
2001). The presence of a homologue of Nr-13 in HVT
provides the first evidence of a Bcl-2-like sequence in the
genome of an -herpesvirus. The present article deals with
the characterization of this new viral Bcl-2 homologue,
which we propose to call vNr-13, because of its striking
similarity to chicken Nr-13 (63.7% amino acid identity). We
show that vNr-13 behaves as a cell death inhibitor and has
a negative regulatory effect on the cell cycle. Together our
results suggest that vNr-13 could mediate HVT effect on
cell survival and the cell cycle.
Results
Two open reading frames (ORFs) potentially encoding a
homologue of the apoptosis inhibitor Nr-13 have been re-
cently found in the short repeats (IRs and TRs) of the HVT
genome (Kingham et al., 2001; Afonso et al., 2001).
Genomic organization of these loci is shown in Fig. 1. Both
ORFs are split into two exons separated by a short intron.
They potentially encode an Nr-13 homologue, having all
four Bcl-2 homology domains (BH domains) and an hydro-
phobic tail, which may interact with the network of intra-
cellular membranes (TM domain). We propose to call this
viral protein vNr-13 (for “viral Nr-13”). VNr-13 is 179
amino acids long, with a calculated molecular mass of 19.0
kDa and a calculated isoelectric point (IP) of 5.0. Afonso et
al. (2001) originally identified an ORF in the HVT genome,
Fig. 1. Organization of the vnr-13 gene. Genomic organization of the
vnr-13 viral loci. (Top) Open reading frame and flanking sequences of
vnr-13. Amino acid sequence is shown above the nucleotidic sequence.
The sequence of the long vNr-13 isoform is shown in block letters,
one-letter code. The N-terminal moiety of the short isoform vNr-13s
encoded by the first 84 nucleotides of the intron is in italics. Splice donor
and splice acceptor sites are underlined. (Bottom) Organization of vNr-13
isoforms, showing functional domains of the proteins encoded by two
exons (vNr-13L) or one exon (vNr-13s), together with conserved -helices
present in the Bcl-2 family of apoptosis inhibitors.
257A. Aouacheria et al. / Virology 316 (2003) 256–266
corresponding to exon 1 and the first 84 nucleotides of the
intron. This ORF potentially encodes a truncated vNr-13
isoform, lacking part of the BH2 domain and the TM do-
main (Fig. 1). This isoform is named here vNr-13s (for
vNr-13 “short”). VNr-13s is 162 amino acids long with a
calculated molecular mass of 17.3 kDa and a calculated IP
of 5.7. Sequence comparison using the PSORT II program
did not show any homology between the C-terminal moiety
of vNr-13s and protein sequences in available databases.
vNr-13 exhibits more than 80% similarity and 63.7%
identity with chicken Nr-13 (Table 1 and Fig. 2). These
values clearly identify this protein as the viral form of
Nr-13. Alignment of both vNr-13 isoforms with Bcl-2 fam-
ily members is shown in Fig. 2. vNr-13 is the closest
homologue of chicken Nr-13 known to date. This high
homology suggests that it appeared recently during evolu-
tion (Aouacheria et al., 2001). Importantly, this homology is
found not only within domains BH1 and BH2 but also in the
N-terminal half of the protein (BH4 and BH3). Therefore, in
Table 1
Comparison between viral and cellular Bcl-2 family members
VNr-13/Nr-13 Gallus gallus 63.7%
LMH-5W ASFV/Bcl-XL Sus crofa 19.3%
vBcl-2 HVS/Bak Homo sapiens 19.4%
M11 MHV68/Bcl-2 Rattus norvegicus 22.6%
BHRF1 HVP/Bcl-w Homo sapiens 23.6%
KsBcl-2 HHV8/Bcl-w Homo sapiens 23.4%
VBcl-2 BHV4/Bcl-2 Homo sapiens 19.2%
VBcl-2 BHV4/Bcl-XL Homo sapiens 19.2%
Note. Values represent percentage of amino acid identity. Similarity
searches were performed with BLAST and ALIGN (GENESTREAM).
vNr-13 (this report), chicken Nr-13 (AAK54806), LMH-5W African swine
fever (Q07809), pig Bcl-XL (O77737), vBcl-2 Saimiri (CAA73630), hu-
man Bak (Q16611), M11 MHV68 (AAB50016), rat Bcl-2 (P49950),
BHRF1 herpesvirus papio (AAD26543), human Bcl-w (Q92843), KsBcl-2
HHV8 (AAB62596), vBcl-2 BHV4 (AAD34361), human Bcl-2 (P10415),
and human Bcl-XL (Q07817).
Fig. 2. Alignment of vNr-13 with the Bcl-2 family. Human Nrh (AJ458330) mouse (AAC83150) and rat (AY029163) Diva/Boo, chick (AAK54806) and quail
(Q90343) Nr-13, Danio rerio EST clone AAL32471, Xenopus laevis IMAGE clone (BI443963), chick Bcl-XL (Q07816), LMH-5W (Q07819), vBcl-2 Saimiri
(CAA73630), vBcl-2 BHV4 (AAD34361), and KsBcl-2 HHV8 (AAB62596). Identical amino acids are highlighted (black); similar amino acids are shaded.
BH1–4 domains predicted C-terminal TM domain are shown.
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contrast to other viral Bcl-2-related proteins (e.g., BHRF-1,
ORF-16, or v-Bcl-2) vNr-13 has homology with its cellular
counterpart throughout the four functional domains BH1-4.
Thus, vNr-13 is the only viral Bcl-2-like protein identified
to date, having a true BH4 domain. In addition, the con-
necting region between BH1 and BH2 is unexpectedly
highly conserved. However, the TM domain of vNr-13
differs from cellular Nr-13 TM domain, raising the possi-
bility of distinct subcellular localization. Comparison of
virus-encoded Bcl-2 members with their cellular counter-
parts points out this exceptionally high similarity between
vNr-13 and Nr-13 (Table 1).
To evaluate if vNr-13 could be expressed in vertebrate
cells, we have cloned the corresponding ORF into the
pEGFPC1 expression vector and derived stable transfec-
tants using the quail QM7 cell line. As shown in Fig. 3,
QM7 cells transfected with constructs encoding vNr-13
fused to GFP express a protein of about 60 kDa which cross
reacts with anti-Nr-13 and anti-GFP antibodies. In cells
transfected with pEGFPC1 (empty vector), no protein was
detected with the anti-Nr-13 polyclonal antibody, whereas
anti-GFP antibody revealed a protein of 30 kDa apparent
molecular weight, corresponding to GFP. These results
show that the vnr-13 ORF can be efficiently translated and
give rise to a protein of expected molecular weight, which
is specifically recognized by an anti-Nr-13 polyclonal anti-
body.
The subcellular localization of vNr-13 was studied by
confocal fluorescent microscopy on chicken embryonic fi-
broblasts (CEFs) transiently transfected with pEFPC1 vec-
tors expressing GFP or GFP-vNr-13 fusion. As shown in
Fig. 4, vNr-13 partly colocalizes with Mitotracker, suggest-
ing that it can associate with mitochondria as do other
Bcl-2-like proteins. Inspection of Fig. 4 also reveals vNr-13
Fig. 3. Expression of vNr-13 in QM7 cells. (Top). QM7 cells were stably transfected by pEGFPC1 empty vector or pEGFPC1 constructs coding for
GFP-vNr-13. Immunoblotting with anti-GFP antibody was used to detect protein expression. Position of GFP and GFP-vNr-13 fusion protein is indicated
on the right. (Middle) Detection of GFP-vNr-13 with anti-Nr-13 antibody. (Bottom) Calibration with antipaxillin antibody.
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specifically localized proximal to the nuclear envelope. Fur-
thermore, intracellular fluorescence not associated with mi-
tochondria is distributed in a pattern reminiscent of the
endoplasmic reticulum.
We then checked if vNr-13 was actually expressed in
HVT-infected cells. Thus, we performed Western blotting
experiments on protein extracts from CEFs infected or not
by HVT. Fig. 5A shows that a strong signal, corresponding
to a protein with an apparent molecular weight of 20 kDa,
is detected in HVT-infected cells, but not in noninfected
CEFs. This indicates that the vNr-13 protein is accumulated
in HVT-infected cells. The molecular weight of the detected
protein suggests that it actually corresponds to the long, but
not to the short, isoform. Since the polyclonal antibody used
in this study could potentially detect endogenous cellular
Nr-13, RT-PCR experiments were carried out using oligo-
nucleotides designed to specifically amplify the vnr-13 tran-
script (spliced RNA encoding the long vNr-13 isoform, see
Materials and methods for oligonucleotide sequences) but
not cellular Nr-13 transcript. An amplification product of
expected size (577 base pairs) was obtained in HVT-in-
fected cells but not in naive CEFs, thus confirming that
vnr-13, but not vnr-13s, was actually expressed at both RNA
and protein level in infected cells (Fig. 5B).
The high similarity between viral and cellular Nr-13
indicated that vNr-13 could inhibit apoptosis, suggesting
that HVT-infected cells could be more resistant to cell
death. To test this, CEFs infected or not with HVT were
submitted to serum starvation for 48 h. Cell death was then
evaluated by using trypan blue exclusion test. The results
(Fig. 6) showed that cell death due to serum starvation is
significantly lower in HVT-infected cells compared to non-
infected cells. These data supported the idea that HVT could
protect host cells against cell death via the expression of
vNr-13.
Direct demonstration of the antiapoptotic effect of
vNr-13 was conducted using stably transfected COS-7 or
quail QM7 cells expressing GFP or GFP-vNr-13. As shown
in Fig. 7A, vNr-13 efficiently protects COS-7 cells from cell
death due to serum starvation. Similarly, following treat-
ment with the protein kinase C inhibitor staurosporin (SP),
QM7 cells transfected with empty vector die by apoptosis,
whereas QM7 cells expressing vNr-13 were significantly
more resistant to SP (Fig 7B).
We also studied the effect of vNr-13 on the response of
QM7 cells to thapsigargin (TG), a death inducer that acti-
vates an ER-dependent pathway (Zhu et al., 1996; Scorrano
et al., 2003). As shown in Fig. 8A, vNr-13 prevents TG-
induced cell death in QM7 cells. Direct measurement of
intracellular caspase activity using the fluorescent substrate
analogue D2R showed that vNr-13 prevents ER-dependent
caspase activation in vivo (Fig. 8B).
In addition to its effect on apoptosis, Bcl-2 and a number
of Bcl-2 homologues were described as cell-cycle inhibi-
tors. This may have important biological consequences and
may explain, at least in part, why tumors expressing Bcl-2
to a high level grow slowly. However, the effect of viral
Bcl-2 homologues on the cell cycle is still controversial. We
have investigated the effect of vNr-13 on the cell cycle by
measuring its effect on cell growth in QM7 cells. Figure 9
shows that QM7 expressing GFP-vNr-13 exhibit a markedly
reduced rate of proliferation compared to naive cells or to
GFP-expressing cells. In accordance with this observation,
vNr-13 was found to inhibit serum-induced reentry into
S-phase of G1-arrested QM7 cells (Table 2). Together this
suggested that vNr-13 may have cell-cycle inhibitory effect.
Discussion
Marek’s disease virus is a highly pathogenic -herpes-
virus causing acute lymphoma in chickens. In contrast,
Fig. 4. Subcellular localization of vNr-13. Confocal imaging on CEFs transiently transfected with pEGFPC1 vector encoding GFP-vNr-13 fusion protein.
Image in the middle row shows Mitotracker red fluorescence. Merged pictures are shown in the right panel.
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HVT is a nonpathogenic -herpesvirus used to vaccinate
against MDV in commercial flocks (Witter, 2001). Under-
standing the biology of HVT may help improve vaccination
efficiency. This could have significant economic impact and
important implications for the development of human anti-
cancer vaccines.
The genome of HVT contains two identical open reading
frames, encoding a close homologue (63.7% amino acid
identity) of the chicken apoptosis inhibitor Nr-13 (Kingham
et al., 2001; Afonso et al., 2001). The Nr-13 protein is a
Bcl-2 homologue containing four Bcl-2 homology domains
(BH domains) and a hydrophobic transmembrane domain
(TM) at its carboxyl-terminus. In addition, comparison be-
tween Nr-13 and vNr-13 shows a high degree of conserva-
tion of the connecting region between BH1 and BH2 do-
mains suggests that it may have a functional role within
Fig. 5. Expression of vNr-13 in HVT-infected CEFs. (A) Immunoblot showing vNr-13 protein in CEFs infected by the FC126 strain of HVT. Cell lysates
from CEFs infected (HVT) or not (n.i.) with FC126 were prepared 72 h postinfection. Antipaxillin antibody was used for calibration. (B) RT-PCR analysis
showing that vNr-13 transcript can be detected in HVT-infected CEFs, but not in uninfected cells. The size of the amplification product corresponds to the
long isoform (577 base pairs).
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Nr-13. This will be confirmed by site-directed mutagenesis.
Moreover, vNr-13, as well as Nr-13, lacks caspase cleavage
site within the connecting loop between BH4 and BH3, a
typical feature of a number of viral Bcl-2 homologues
(Bellows et al., 2000).
The cellular nr-13 gene contains two exons and one
intron (our unpublished results). The first exon encodes
BH4, BH3, BH1, and part of BH2 domain, whereas exon 2
encodes the rest of the BH2 domain and the TM domain.
One copy of the viral nr-13 gene (vnr-13) is found in each
of the short repeats—IRs and TRs (see Kingham et al.,
2001)—of the HVT genome. Vnr-13 has the same organi-
zation as the cellular nr-13 gene, with conservation of in-
tron–exon boundaries (Fig. 1). In contrast, no bcl-2-like
sequence is found in the genome of MDV. In accordance
with these observations, there is experimental evidence that
HVT, but not MDV, inhibits cell death in the DT40 chicken
cell line (Ewert and Duhaway, 1999). We show here that
HVT prevents cell death due to serum withdrawal in CEFs.
Moreover, RT-PCR and Western blotting revealed that
vnr-13 transcript containing both exons as well as vNr-13
protein accumulate in HVT-infected cells. In addition, dur-
Fig. 6. HVT protects CEFs from cell death. Trypan blue exclusion test.
Infected (HVT)—72 h postinfection—or control CEFs (n.i.) were seeded
in 60-mm dishes (105 cells) and serum-starved 24 h later. Cells were
trypsinized 48 h after serum withdrawal and immediately analyzed for
trypan blue exclusion. Histograms represent percentage of cell deaths
expressed as means of three independent experiments. Standard error mean
is shown. () Serum starved cells; () nonstarved control cells.
Fig. 7. vNr-13 is an inhibitor of apoptosis. Protective effect of vNr-13 against death-inducing agents. Representative data obtained with three different clones.
(A) Serum withdrawal. (Top) Growth kinetics of COS-7 cell clones stably expressing GFP or GFP-vNr-13 fusion. Cells were collected every 24 h (time,
horizontal axis). Mortality was measured using trypan blue exclusion test (%, vertical axis). (Bottom) Detection of GFP and GFP fusion proteins in COS cells
lysates by Western blotting, using anti-GFP antibody. (B) Staurosporine. QM7 cells were treated with 10 M staurosporine (SP) for 6 h. Percentage of
apoptotic nuclei was determined using Hoescht staining. Histograms represent means of three independent experiments. Standard error of the mean is shown.
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ing the virus life cycle, vNr-13 is expressed as an imme-
diate–early gene (our unpublished data). These results sug-
gest the vnr-13 gene may be responsible, at least in part, for
HVT’s ability to inhibit apoptosis.
Our results indicate that the major product of the vnr-13
gene is the spliced mRNA encoding a complete Bcl-2 type
protein. However, we cannot exclude that, at least in certain
circumstances, a truncated vNr-13s isoform, with a different
carboxyl-terminal moiety, could be synthesized from the
nonspliced transcript. This truncated form corresponds to a
putative ORF including exon 1 and extends 84 nucleotides
into the intron, where it is interrupted by a stop codon.
However, this isoform could not be detected either by West-
ern blotting or RT-PCR, suggesting that vNr-13s may not be
present in HVT-infected CEFs. Together, our results show
that the vNr-13 long isoform is an efficient inhibitor of
apoptosis. This may be important to maintaining viable cells
to support either lytic or latent infection. In addition, vNr-13
was found to exhibit antiproliferative effect. Generation of
a deleted HVT mutant lacking the vNr-13 ORF will help
resolve the importance of these effects to the viral cycle.
vnr-13 is the first bcl-2 family member known to date in
-herpesviruses. However, bcl-2-related sequences are
found repeatedly in -herpesviruses (Bellows et al., 2000).
Although these sequences were picked up from host ge-
nome, their products exhibit low homology with cellular
Bcl-2 family members known to date (see Table 1). Thus,
vnr-13 is the only viral bcl-2 member whose cellular ances-
tor is clearly identified, which may indicate that this gene
was picked up recently. Moreover, contrary to bcl-2-like
Fig. 8. vNr-13 prevents thapsigargin-induced cell death. QM7 cells were treated with 2 M thapsigargin (TG) for 48 h. (A) Percentage of apoptotic nuclei
was determined using Hoescht staining. Histograms represent means of three independent experiments. Standard error mean is shown. (B) In vivo caspase
activation was determined by FACS by measuring D2R fluorescence. Representative data obtained with three different clones.
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genes in -herpesviruses (and other DNA viruses) which are
intronless, and probably arisen from cDNA insertion,
vnr-13 and cellular nr-13 share the same genomic organi-
zation, with two exons and one intron. One explanation
could be that vnr-13 comes from a reverse-transcribed un-
spliced precursor RNA. Alternatively, another possibility
comes from the observation that nr-13 gene expression is
strongly activated in cells infected by the Rous sarcoma
virus (RSV). If coinfection by this retrovirus (RSV) and an
HVT ancestor actually occurred, which is not unlikely
(Haig, 2001), recombination events at the actively tran-
scribed cellular nr-13 locus could have been favored. Indeed
there is evidence that DNA recombination is enhanced by
chromatin decondensation (Curcio and Morse, 1996; Huang
et al., 2001). In the MDV genome, the vIL-8 gene may have
been picked up by a similar mechanism. Indeed, expression
of the cellular homologue of vIL-8 is also activated upon
RSV infection (Be´dard et al., 1987). Together, these obser-
vations suggest an evolutionary mechanism for herpesvirus
genomes in which coinfection with other viruses drives the
acquisition of new genes from the host cell through recom-
bination at the DNA level.
Materials and methods
vNr-13 cloning
PCR was used to generate two products from the HVT
strain FC126. PCR was carried out for 25 cycles with
AmpliTAQ (Perkin–Elmer). Conditions were 94°C 45 s;
54°C 20 s; 72°C 60 s. One product contained both exons
and the single predicted intron (vNr-13). The second prod-
uct used the same 5 primer, but the 3 primer annealed
within the intron, utilizing an in-frame stop codon to gen-
erate a truncated product (vNr-13s).
Common 5 primer: AGATCTGAATTCTATGGCT-
GACTCCCTGAAGGAAG
vNr-13 3 primer: AGATCTGGATCCCTCGAG-
CAAGACAGCGTCCGATACACTTTAG
vNr-13s 3 primer: AGATCTGGATCCGCGGCC-
TGGTGGCTGGCGGCCAGGGCTA
Products were subcloned into the pEGFPC1 vector
(Clontech) in-frame with the green fluorescent protein ORF.
All constructs were sequenced (MWG Biotech) to insure
that no errors were introduced by PCR.
Cell lines and viruses
HVT-FC126 strain was propagated in secondary CEFs
prepared from 7-day-old chicken embryos QM7 and CEFs
cells were grown in 5% fetal calf serum (FCS) plus 1%
chicken fetal serum (CFS) (Biomedia). Cells were trans-
fected using Fugene 6 Reagent (Roche) as described
(Aouacheria et al., 2001). Stable transfectants were selected
with 500 g/ml G418 (Biomedia).
Apoptotic assays
Cells were treated with different apoptosis-promoting
stimuli, including serum withdrawal for 2 days, 1 M stau-
rosporine for 6 h, and 2 M thapsigargin for 48 h. In
negative control experiments an equal volume of DMSO
solvant was added to the culture medium.
Quantification of nuclear apoptosis
Hoescht 33258 (Sigma) was used to assess apoptosis
nuclear changes as described (Aouacheria et al., 2001). A
minimum of 100 cells from three different areas of each
plate was counted for each experimental point.
Table 2
vNr-13 inhibits S-phase entry
% BrdU-positive nuclei
GFP vNr-13
Clone 1 39.7 19.7
Clone 2 40.1 27.3
Clone 3 37.1 21.1
Mean 39.7 19.7
S.E.M. 1.6 4
Note. Cos cells stably expressing GFP or GFP-vNr-13 were synchro-
nized in G1 by serum starvation for 2 days in the presence of 1 M
aphidicolin. In these conditions, more than 90% of the cells are arrested in
G1. Cell-cycle reentry was induced by serum addition. S-phase entry was
evaluated using BrdU pulse labeling 10 h after serum addition. Results from
three independent experiments are shown. Means and standard error of the
means are shown. Representative data obtained with three different clones.
Fig. 9. Inhibitory effect of vNr-13 on cell proliferation. GFP-vNr-13-
expressing clones (COS-7) display decreased growth kinetics relative to
GFP-expressing clone. Growth kinetics of representative vector control and
vNr-13-expressing clones were analyzed for 5 days. Cell number was
determined at daily intervals using trypan blue to estimate viable cell
number. Data are means of triplicate counts and are representative of three
independent experiments carried out with different clones.
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Trypan blue exclusion test
The test was performed as previously described
(Aouacheria et al., 2001).
Phiphilux staining of intact cells
Caspase activity (predominantly caspase-3) was detected
in intact QM7 cells using (L-Asp)2 rhodamine 110 (D2R).
Floating cells present in the supernatant and those collected
as single-cell suspension by trypsinization were mixed.
Cells (5  104) were thereafter incubated for 30 min in
culture medium containing 100 M D2R. Free (cleaved)
Rhodamine 110 emission was measured using FL2 channel.
Western blotting
Gels were loaded with 30 g protein per lane. Western
blots were carried out as described (Aouacheria et al.,
2001). The blots were then incubated with the monoclonal
anti-GFP antibody (Roche) (1:500), monoclonal antipaxillin
(Zymed Laboratories clone Z035) (1:200), monoclonal an-
ticytochrome c (R&D Systems, clone 7H8.2C12) (1:200),
monoclonal anti-mouse IgG (Dako) (1:2500), or protein A
purified polyclonal anti-Nr-13 (Gillet et al., 1995).
RT-PCR
Exponentially growing CEF were infected with 1  104
plaque forming units of HVT strain FC126 (m.o.i.  0.01).
Total RNA was prepared using the FastTrack kit (Invitro-
gen). Reverse transcriptase (Gibco) was primed with vNr-13
3 specific primer (see above). PCR was carried out for 30
cycles with AmpliTAQ (Perkin–Elmer) using 5 primer and
vNr-13 primer. Conditions were as follows: 94°C, 45 s;
54°C, 20 s; 72°C, 60 s. Results were analyzed by electro-
phoresis through a 1.5% agarose gel.
Confocal microscopy
Transfections of CEFs with pEGFPC1 expression vec-
tors were carried out as described (Aouacheria et al., 2001).
Images were obtained from live cells using a Zeiss LSM
510 confocal microscope as previously described
(O’Donnell et al., 2002).
Labeling of intracellular organelles
Cells were loaded with 250 nM Mitotracker Red
CMXRos and 1 M ER-Tracker Blue-White DPX (Molec-
ular Probes) to visualize mitochondria and ER, respectively.
Subsequent manipulations were performed as previously
described (Aouacheria et al., 2001).
Growth curves
QM7 cells were rinsed with PBS and collected as single-
cell suspensions by trypsinization. Cells were plated out at
a concentration of 2.5  103 cells/well in a 24-well plate
(Costar) in triplicate. Twenty-four hours after seeding (day
1), the medium was renewed and cells were cultured for an
additional 4 days. Cell growth was assessed at 24-h intervals
using trypan blue exclusion test. At least three independent
clones were analyzed.
BrdU incorporation assay
Briefly, cells seeded at the density of 104 cells were
grown onto eight-well-cell-culture chamber. Serum depri-
vation was imposed for 2 days in presence of 1 M aphidi-
colin (Sigma) before serum was added for 10 h. BrdU (10
M, Sigma) was added to the media for 1 h before cells
were washed three times with 0.5% Tween 20, 1% BSA in
PBS. Cells were then fixed with 70% EtOH for 30 min,
treated with 2 N HCl, 0.5% Triton X-100 in PBS for another
30 min, and neutralized with Na2B4O7 pH 8.5 in PBS. After
a 30-min blockade in washing buffer, cells were stained
with anti-BrdU MAb BU-33 (Sigma) for 1 h at room tem-
perature followed by Alexa green conjugated anti-mouse
IgG (Molecular Probes) for an additional 1 h at room tem-
perature. The preparation was counterstained with Hoechst
33258 in PBS (1 g/ml) for 30 min and examined under a
fluorescence microscope (40 objective, Zeiss).
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